
Please type a plus sign (+) inside this box -> +



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM Total Number of Pages in This Submission 1		Application Number	09/155,739
		Filing Date	September 11, 1998
		First Named Inventor	Yednock, Ted A.
		Group Art Unit	1642
		Examiner Name	Mrs. Wallace
		Attorney Docket Number	015270001430
	ENCL	OSURES (check all that apply)	ER 9
Fee Transmittal Form		ment Papers Application)	After Allowance Communication Group
Fee Attached	☐ Drawin	g(s)	Appeal Communication to Appeals and Interference
Amendment / Response	Licensi	ing-related Papers	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
		n Routing Slip (PTO/SB/69) ccompanying Petition	Proprietary Information
_		n to Convert to a ional Application	Status Letter
Extension of Time Request		of Attorney, Revocation e of Correspondence Address	Other Enclosure(s) (please identify below):
Express Abandonment Request	☐ Termin	al Disclaimer	34 References
	Request for Refund		Return Postcard
Information Disclosure Statement C		umber of CD(s)	
Certified Copy of Priority Document(s) Ren		l =	s authorized to charge any additional fees to 1430.
Response to Missing Parts/ Incomplete Application			
Response to Missing Parts under 37 CFR 1.52 or 1.53			
SIGN	ATURE OF A	APPLICANT, ATTORNEY,	OR AGENT
Firm Townsend and Townsend	ownsend and	Crew LLP	
Individual name Andrew T. Serafi	ni, Ph.D. 	Reg N	o. 41,303
Signature Andur	V. Es		
Date October 9, 2001	10		
	CEI	RTIFICATE OF MAILING	
hereby certify that this correspondence class mail in an envelope addressed to:	is being depos Assistant Com	sited with the United States Pos missioner for Patents, Washing	stal Service with sufficient postage as first gton, D.C. 20231 on this date: October 9, 2001
Typed or printed name Kathy Johns	ton ,)	
Signature	1 1		Date October 9, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3175607 v1

I hereby certify that this correspondence is being deposited with the United

States Postal Service as first class mail in an envelope addressed to

Assistant Commissioner for Patents Washington, D.C. 20231

n Actober 9,2001

TOWNSEND and TOWNSEND and CREW LLP

<u>PATENT</u>

Attorney Docket No.: 015270-001430US

Client Reference No.: 120-US-CIP1

RECHOENTER TONINGS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OCT 1 8 2001

In re application of:

Mary M. Bendig et al.

Application No.: 09/155,739

Filed: September 11, 1998

For: THERAPEUTIC USES OF

HUMANIZED ANTIBODIES AGAINST

ALPHA-4 INTEGRIN

Examiner:

Gambel, P.

Art Unic.

1644

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

§1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. Also enclosed is a copy of the Search/Examination report corresponding to the PCT application. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Elan Pharmaceuticals Application No.: 09/155,739

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed after the mailing date of a first Office Action. This Office Action was an Election/Restriction Requirement and therefore is not an action on the merits.

Therefore, Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action on the merits. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Andrew T. Serafini

Reg. No. 41,303

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 650-326-2400 Fax: 650-326-2422

ATS:rnh

PA 3173153 v2